Jump to the top of the page

Investment Banking

The Quarterly Rx: Q3 2022 U.S. Biopharma Recap

While biopharma markets stabilized in Q3 2022—providing issuers with the most constructive financing environment we have seen year-to-date—macroeconomic issues remain the key headline risk for the near term. Key biopharma indices bounced off multiyear lows, driven by encouraging signs of M&A, meaningful positive clinical news, and broad sector short covering. William Blair's Biopharma team shares perspectives in “The Quarterly Rx: Q3 2022 U.S. Biopharma Recap.

Complete the form below to download your copy of the report.

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

Subscribe to News Alerts

More News and Insights

  • Mama’s Creations, Inc.: Initiation of Research Coverage

    William Blair initiated research coverage of Mama’s Creations, Inc., a leading manufacturer and marketer of on-trend fresh deli-prepared foods sold in more than 12,000 grocery, mass, club, and convenience stores in the U.S.

    Read more

  • Economics Weekly: Why Wait?

    In this Economics Weekly, Richard de Chazal discusses several reasons the Fed could decide to pull the trigger next week and not wait until September.

    Read more

  • Core & Main, Inc.: Initiation of Research Coverage

    William Blair initiated research coverage of Core & Main, Inc., a leading distributor of waterworks products used in municipal, nonresidential, and residential markets.

    Read more
See more insights

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures